The Phase-3 trials for the vaccine were conducted on 25,800 volunteers. Bharat Biotech has submitted the Phase-3 efficacy data earlier this week. Covaxin, the country’s first indigenous COVID-19 vaccine, was developed with seed strains received from the National Institute of Virology.Explained | What Phase 3 data submission of Covaxin means, how close is it to WHO approval, and comparison with other jabs
The Phase-3 trials for the vaccine were conducted on 25,800 volunteers. Bharat Biotech has submitted the Phase-3 efficacy data earlier this week. Covaxin, the country’s first indigenous COVID-19 vaccine, was developed with seed strains received from the National Institute of Virology.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment